Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Agilon Health (AGL) to $5 from $6 and keeps an Overweight rating on the shares. The firm cites a “frustrating quarter” given the PYD issues. The thesis remains largely unchanged, with Wells continuing to see positive leverage to improving MA rates and downstream margin recovery story. The firm is lowering forward revenue/profit somewhat to account for Agilon’s expected trajectory.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health: Buy Rating Supported by Medicare Advantage Leverage and Margin Recovery
- Agilon Health price target raised to $3 from $2 at Barclays
- Agilon Health Inc’s Mixed Q1 Earnings Call Review
- Cautious Hold Rating on Agilon Health Amid Uncertainties Despite Strong Q1 FY25 Performance
- Cautious Outlook on Agilon Health: Financial Challenges and Strategic Concerns Drive Sell Rating